Methotrexate for high-grade osteosarcoma in children and young adults

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Van Dalen, Elvira C ^a   De Camargo, Beatriz ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Adolescent; Antineoplastic agents *therapeutic use ; Bone neoplasms *drug therapy ; Child; Cisplatin therapeutic use ; Humans; Methotrexate *therapeutic use ; Osteosarcoma *drug therapy ; Young adult

Indexed keywords

CISPLATIN; CREATININE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

CANCER GRADING; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CREATININE CLEARANCE; DRUG FATALITY; HUMAN; NAUSEA; NEEDLE BIOPSY; OSTEOSARCOMA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN INDURATION; SYSTEMATIC REVIEW; VOMITING;

EID: 70249094258     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006325.pub2     Document Type: Review

References (77)

1. Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, Anzai T, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. Journal of Clinical Oncology 1985;3:1101-1104.
2. Bacci G, Avella M, Picci P, Ruggieri P, Biagini R, Ferruzzi A, et al.Neoadjuvant chemotherapy for osteosarcoma of the extremities: the Rizzoli Institute experience. La Chirurgia Degli Organi di Movimento 1990;75:57-59.
3. Bacci G, Picci P, Ferrari S, Avella M, Prever BA, Ruggieri P, et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute. Cancer Treatment and Research 1993;62:299-308.
4. Beppu Y, Fukuma H, Yokoyama R, Kawai A. Historical improvement in treatment for osteosarcma and bone tumor registry. Journal of the Japanese Orthopaedic Association 1992;66:S3-S4.
5. Bramwell VHC, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, et al.A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. Journal of Clinical Oncology 1992;10:1579-1591.
6. Brenes-Saenz A, Lobo-Sanahuja F, Garcia I, Vargas G, Orlich F. Results of the treatment of osteosarcoma at the National Children's Hospital of Costa Rica. Boletín Médico del Hospital Infantil de México 1986;43:544-549.
7. Brunat-Mentigny M, Blondet R, Bouffet E, Chauvot P, Moyen B, Philip T. Initial chemotherapy and conservative surgery in the current treatment of osteosarcoma. Apropos of 24 cases. Annales de Pédiatrie (Paris) 1984;31:773-778.
8. Burgers JMV, Van Glabbeke M, Busson A, Cohen P, Mazabraud AR, Abbatucci JS, et al. Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 1988;61:1024-1031. (Pubitemid 18058619)
9. Cortes EP, Holland JF, Glidewell O. Osteogenic sarcoma studies by the Cancer and Leukemia Group B. National Cancer Institute Monograph 1981:207-209.
10. Cortes EP. Adjuvant chemotherapy for primary osteosarcoma: a Cancer and Leukemia Group B experience. Adjuvant therapy of cancer III. New York: Grune, 1981:201-210.
11. Delepine N, Desbois JC, Delepine G, Cornille H, Jasmin C, Favre R. Comparative study of 3 successive treatment protocols of osteogenic osteosarcoma in children, adolescents and young adults. Apropos of 100 cases. Annales de Médecine Interne (Paris) 1989;140:32-35.
12. Delepine N, Delepine G, Desbois JC. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery. Cancer Treatment and Research 1993;62:327-332.
13. Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Creagan ET, Pritchard DJ, et al. A controlled pilot study of high-dosemethotrexate as postsurgical adjuvant treatment for primary osteosarcoma. Journal of Clinical Oncology 1984;2:152-156.
14. Edmonson JH. High-dose methotrexate in osteosarcoma-Mayo Clinic studies. National Cancer Institute Monographs 1987;5:67-69.
15. Eilber FR, Grant T, Morton DL. Adjuvant therapy for osteosarcoma: preoperative and postoperative treatment. Cancer Treatment Reports 1978;62:213-216.
16. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. Journal of Clinical Oncology 1987;5:21-26.
17. Gherlinizoni F, Picci P, Bacci G, Campanacci D. Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgicalmargins and tumor necrosis: Istituto Rizzoli experience. Annals of Oncology 1992;3:23-27.
18. Gilchrist GS, Ivins JC, Ritts Jr RE, Pritchard DJ, Taylor WF, Edmonson JM. Adjuvant therapy for nonmetastatic osteogenic sarcoma: an evaluation of transfer factor versus combination chemotherapy. Cancer Treatment Reports 1978;62:289-294.
19. Gill M, McCarthy M, Murrells T, Silcocks P. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years. Lancet 1988;1:689-692.
20. Graham-Pole J, Saleh R, Springfield D, Vander Griend R, Spanier S, Dickson N, et al. Neo-adjuvant chemotherapy for limb osteosarcoma. Neo-adjuvant chemotherapy. Vol. 169, Colloque INSERM/John Libbey Eurotext Ltd, 1988:515-520.
21. Graziani G, Priori T, Fiorentini G, Molinari M, Tienghi A. Neoadjuvant intraarterial chemotherapy for sarcoma of the extremities. La Radiologia Medica (Torino) 1990;80:474-476.
22. Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. Journal of Clinical Oncology 1990;8:1988-1997.
23. Isu K, Yamawaki S, Usui M. A group study of neoadjuvant chemotherapy for osteosarcoma - Results and problems of T-12 protocol. Journal of the Japanese Orthopaedic Association 1992;66:S9-S10.
24. Jaffe N, Frei III E, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. New England Journal of Medicine 1974;291:994-997.
25. Jaffe N. Progress report on high-dose methotrexate (NSC-740) with citrovorumrescue in the treatment ofmetastatic bone tumors. Cancer Chemotherapy Reports 1974;58:275-280.
26. Jaffe N, Smith E, Abelson HT, Frei III E. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. Journal of Clinical Oncology 1983;1:251-254.
27. Kalifa C, Razafindrakoto H, Vassal G, Contesso G, Vanel D, Edeline V, et al.Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute. Cancer Treatment and Research 1993;62:347-349.
28. Levine AS, Appelbaum FR, Graw Jr RG, Magrath IT, Pizzo PA, Poplack DG, et al.Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. Cancer Treatment Reports 1978;62:247-250.
29. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. Journal of Clinical Oncology 2000;18:4028-4037.
30. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al.The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. New England Journal of Medicine 1986;314:1600-1606.
31. Link MP. The multi-institutional osteosarcoma study: an update. Cancer Treatment and Research 1993;62:261-267.
32. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al.Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. Journal of Clinical Oncology 1998;16:2452-2458.
33. Miser JS, Krailo M. Osteosarcoma in adolescents and young adults: new developments and controversies. The Childrens Cancer Group (CCG) studies. Cancer Treatment and Research 1993;62:287-291.
34. No authors listed. Randomized trial of adjuvant chemotherapy in osteogenic osteosarcoma: comparison of altering sequential administrations of high doses of adriamycin, methotrexate, and cyclophosphamide with a 6-month administration of high-dose adriamycin followed by a low-dose semicontinuous chemotherapy. EORTC Osteosarcoma Working Party Group. Recent Results in Cancer Research 1978;68:28-32.
35. No authors listed. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group. Cancer 1988;61:1304-1311.
36. Pontz BF, Gutjahr P. Aggressive cytostatic treatment of osteogenic sarcoma in childhood. Deutsche Medizinische Wochenschrift 1981; 106:200-207.
37. Postma A, Kamps WA, Schraffordt KH, Veth RP, Goeken LN, Oosterhuis JW, et al. Osteosarcoma of the leg; treatment results following preoperative chemotherapy. Nederlands Tijdschrift voor Geneeskunde 1986;130:545-548.
38. Postma A, Kamps WA, Schraffordt KH, Veth RP, Goeken LN, Molenaar WM. Osteosarcoma of the limb: an institutional report of 10 years experience with neoadjuvant chemotherapy and delayed surgery. Cancer Treatment and Research 1993;62:361-364.
39. Purfürst C, Beron G, Torggler S, Kotz R, Salzer-Kuntschik M, Winkler K. Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities. Klinische Pädiatrie 1985;197:233-238.
40. Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ, et al.High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 1974;33:1151-1163.
41. Saeter G, Wiebe T, Wiklund T, Monge O, Wahlqvist Y, Engstrom K, et al.Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthopaedica Scandinavica Supplementum 1999;285:74-82.
42. Saleh RA, Graham-Pole J, Cassano W, Abbot F, Vander Griend R, Dickson N, et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 1990;65:861-865.
43. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al.Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
44. Sutow WW, Gehan EA, Dyment PG, Vietti T, Miale T. Multidrug adjuvant chemotherapy for osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treatment Reports 1978;62: 265-269.
45. Tai BC, Machin D, White I, Gebski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine 2001;20:661-684.
46. Wada T, Usui M, Ishii S. Problems in the chemotherapy of osteosarcoma approaches from basic science. Journal of the Japanese Orthopaedic Association 1992;66:S5-S6.
47. Weiner MA, Harris MB, Lewis M, Jones R, Sherry H, Feurer EJ, et al.Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. Cancer Treatment Reports 1986;70:1431-1432.
48. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HDMTX and adriamycin. Preliminary results of the COSS 80 study. Journal of Cancer Research and Clinical Oncology 106;Suppl:1-7.
49. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al.Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. Journal of Clinical Oncology 1984;2:617-624.
50. Fujisaki T, Ishii S, Usui M, Matsuyama T, Asano S, Takahashi M, et al. An effect of IFN with anticancer drugs to osteogenic sarcoma. Hokkaido Journal of Orthopedic and Traumatic Surgery 1991;35:9-14.
51. Jurczyk-Procyk S, Perek D. Alternative chemotherapy of malignant bone neoplasms in children. Problemy Medycyny Wieku Rozwojowego 1990;16:55-68.
52. Kalifa C, Vanel D, Lemerle J. Chemotherapy of osteogenic sarcoma. Revue de Chirurgie Orthopedique 1985;71:429-434.
53. Wada T, Usui M, Ishii S. Importance of intensive chemotherapy in the treatment of osteosarcoma. Hokkaido Journal of Orthopedic and Traumatic Surgery 1991;35:5-10.
54. Zborzil J, JasiÅ,,ska-Rubach M. Results of chemotherapy of osteosarcoma. Nowotwory 1979;Suppl:145-149
55. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al.Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versusmoderate doses) and intraarterial cisplatin. Cancer 1990;65:2539-2553.
56. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al.Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. Journal of Clinical Oncology 1998;16:658-663.
57. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, et al.Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Cancer 2003;97:3068-3075.
58. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Medical Informatics and Decision Making 2008;8:6.
59. Burke GAA, Estlin EJ, Lowis SP. The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer. Cancer Treatment Reviews 1999;25:13-27.
60. Carter SK. The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clinical Trials 1980;3:29-36.
61. Clark JCM, Dass CR, Choong PFM. A review of clinical andmolecular prognostic factors in osteosarcoma. Journal of Cancer Research and Clinical Oncology 2008;134:281-297.
62. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age andmethotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomedicine & Pharmacotherapy 1988;42:257-262.
63. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996;78: 2127-2135.
64. Eselgrim M, Grunert H, Kühne T, Zoubek A, Kevric M, Bürger H, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric Blood and Cancer 2006;47:42-50.
65. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. Journal of Clinical Oncology 1994;12:1443-1451.
66. Grem JL, King SA, Wittes RE, Leyland-Jones B. The role of methotrexate in osteosarcoma. Journal of the National Cancer Institute 1988;80:626-655.
67. Groninger E, Proost JH, De Graaf SSN. Pharmacokinetic studies in children with cancer. Critical Reviews in Oncology/Hematology 2004; 52:173-197.
68. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumours. In: Ries LAG, Smith MA, Gurney JG, et al. editor(s). Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. 1999:99-110.
69. Higgins J, Green S (eds.). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http: //www.cochrane.org/resources/ handbook/hbook.htm 2005.
70. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. Journal of Clinical Oncology 2008;26:4365-4366.
71. Krailo M, Ertel I, Makley J, Fryer CJ, Baum E, Weetman R, et al.A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Medical and Pediatric Oncology 1987;15:69-77.
72. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. Journal of the National Cancer Institute 2007;99:112-128.
73. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al.Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology 2005;23:2004-2011.
74. Kremer LCM, van Dalen EC, Moher D, Caron HN. Childhood Cancer Group. About the Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, issue 3.
75. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al.Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49: 1221-1230.
76. Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treatment Reports 1982; 66:1687-1697.
77. Van den Berg H. Biology and therapy of malignant solid tumors in childhood. Cancer Chemotherapy and Biological Response Modifiers 2002;20:605-625.